📣 VC round data is live. Check it out!

Generation Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Generation Bio and similar public comparables like Veru, Sprint Bioscience, Pluri, FibroGen and more.

Generation Bio Overview

About Generation Bio

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.


Founded

2016

HQ

United States

Employees

115

Financials (FY)

Revenue:
Net Income:

Market Cap

$36M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Generation Bio Stock Performance

Generation Bio has current market cap of $36M.


Generation Bio's stock price is $5.34.

See more trading valuation data for Generation Bio
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$36M0.0%

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Generation Bio Valuation Multiples

Generation Bio Financial Valuation Multiples

As of May 5, 2026, Generation Bio has market cap of $36M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Generation Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Generation Bio Competitors

Generation Bio competitors include Veru, Sprint Bioscience, Pluri, FibroGen, Grace Therapeutics, Jiangsu Wuzhong Pharmaceutical, Boundless Bio, BioXcel Therapeutics, Mendus and Radiopharm Theranostics.

Most Generation Bio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Veru(0.1x)
Sprint Bioscience1.2x1.4x2.0x2.7x
Pluri43.8x(2.7x)
FibroGen14.5x(1.7x)
Grace Therapeutics28.2x(0.8x)(1.4x)
Jiangsu Wuzhong Pharmaceutical
Boundless Bio0.4x0.4x
BioXcel Therapeutics180.1x117.3x(2.2x)(2.3x)

This data is available for Pro users. Sign up to see all Generation Bio competitors and their valuation data.

Start Free Trial

Generation Bio Funding History

Before going public, Generation Bio raised $235M in total equity funding, across 3 rounds.


Generation Bio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-20Series CAtlas Venture; Casdin Capital; Deerfield; Farallon Capital Management; Fidelity; Foresite Capital; Invus; T. Rowe Price; Wellington Management$110MGeneration Bio is a biotechnology company developing non-viral genetic medicines for rare and common diseases using its proprietary platform. The company raised approximately $227.3 million in total funding prior to its S-1 filing from investors including Atlas Venture and others.
Feb-18Series BCasdin Capital; Deerfield; Fidelity; Foresite Capital; Invus; Leerink Partners$100MGeneration Bio is a Cambridge, Massachusetts-based early-stage biotech company developing next-generation gene therapies under its GeneWave platform, using closed-ended DNA to deliver therapeutic proteins for re-dosable, long-lasting treatments targeting severe diseases like hemophilia A, phenylketonuria, skeletal muscle disorders, and eye diseases, aiming to avoid viral vector issues such as immune reactions. The company emerged in 2018 with a $25 million Series A round backed by Atlas Venture, followed by a $100 million Series B round around February 27, 2018, involving Fidelity and other investors including Casdin Capital, Deerfield, Foresite Capital, Invus, and Leerink Partners (SVB Leerink). Subsequently, Generation Bio raised a $110 million Series C round in January 2020, led by T. Rowe Price with participation from Farallon, Wellington Management, and existing investors like Atlas Venture, Fidelity, Invus, Casdin, Deerfield, Foresite Capital, and SVB Leerink, bringing total funding to over $235 million across four rounds to support IND-enabling studies for liver-targeted therapies. The Series C focused on advancing lead programs toward clinical trials. The company continued development, achieving an $848.05 million valuation in June 2020 during its IPO for $199.5 million. Investors in later rounds overlapped with the Series B participants, indicating sustained backing for its platform to scale manufacturing and reach more patients.
Jan-18Series AAtlas Venture$25MGeneration Bio is a Cambridge, Massachusetts-based biotech company developing non-viral gene therapies using closed-ended DNA (ceDNA) delivered via lipid nanoparticles under the GeneWave platform. This approach aims to enable redosable, long-lasting, and scalable treatments for genetic diseases, targeting tissues like liver, eye, central nervous system, lungs, skeletal muscle, with early programs for hemophilia A and phenylketonuria. The company was founded by Atlas Venture and launched in early 2018. In January 2018, Generation Bio emerged with a $25 million Series A financing solely from Atlas Venture, marking its stealth launch. This was rapidly followed by a $100 million Series B round in March 2018, led by Fidelity Management & Research with participation from Invus, Deerfield Management, Casdin Capital, Foresite Capital, and Leerink Partners affiliates, bringing total funding to $125 million. The Series A and B proceeds supported advancement of preclinical programs toward IND-enabling studies, including liver-directed candidates in mouse and non-human primate models, with plans to declare two development candidates within 18 months. CEO Geoff McDonough emphasized 2018 as a critical year for progressing early-stage efforts across multiple tissues. Subsequent rounds included a $110 million Series C in early 2020 led by T. Rowe Price.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Generation Bio

When was Generation Bio founded?Generation Bio was founded in 2016.
Where is Generation Bio headquartered?Generation Bio is headquartered in United States.
How many employees does Generation Bio have?As of today, Generation Bio has over 115 employees.
Is Generation Bio publicly listed?Yes, Generation Bio is a public company listed on Nasdaq.
What is the stock symbol of Generation Bio?Generation Bio trades under GBIO ticker.
When did Generation Bio go public?Generation Bio went public in 2020.
Who are competitors of Generation Bio?Generation Bio main competitors include Veru, Sprint Bioscience, Pluri, FibroGen, Grace Therapeutics, Jiangsu Wuzhong Pharmaceutical, Boundless Bio, BioXcel Therapeutics, Mendus, Radiopharm Theranostics.
What is the current market cap of Generation Bio?Generation Bio's current market cap is $36M.
Is Generation Bio profitable?No, Generation Bio is not profitable.
How many companies Generation Bio has acquired to date?Generation Bio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Generation Bio has invested to date?Generation Bio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Generation Bio

Lists including Generation Bio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial